EANS-News: Epigenomics Signs Distribution Deal with DATEKS for Epi proColon in Turkey

Second distributor to be signed-up for Epi proColon - more expected
to come shortly

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

Subtitle: Second distributor to be signed-up for Epi proColon - more
expected to come shortly

BERLIN and SEATTLE, October 28, 2010 (euro adhoc) - Epigenomics AG
(Frankfurt Prime Standard: ECX), the cancer diagnostics company,
today announced that they have signed an exclusive distributor
agreement with Turkish DATEKS Company Ltd for the commercialization
of Epigenomics' Epi proColon test in Turkey.

Epi proColon is the world's first CE-marked molecular diagnostic test
for the early detection of colorectal cancer in blood. The test uses
Epigenomics' proprietary colorectal cancer biomarker Septin9 in blood
plasma. DATEKS expects to begin marketing the test in Turkey in the
next few weeks.

Cancer is a major threat to public health in Turkey. It is the second
biggest cause of death in the country preceded only by cardiovascular
disease. Despite the establishment of Cancer Early Diagnosis and
Screening Centers (KETEM) in most provinces and the introduction of
colorectal cancer screening standards by the Turkish Ministry of
Health in 2009, screening participation is still low. Current
screening guidelines propose stool testing at two year intervals and
colonoscopy every ten years for men and women aged between 50 and 70
but very few people make use of these options. This has severe
consequences as colorectal cancer is highly curable when detected at
an early still localized stage. Survival chances, however, diminish
once the tumor has spread to distant organs and the disease has
become obvious with patients showing symptoms.

"Epi proColon facilitates the early detection of colorectal cancer,
making screening easier and more patient-friendly than ever," Süha
Dere, Chief Executive Officer of DATEKS explained. "As a blood test,
it is a simple and clean solution for the patients. Importantly, it
can be performed at any time as it does not require any preparation
of the screened individual. We believe that this test can help
significantly to drive acceptance of colorectal cancer early
detection in the Turkish population."

"With DATEKS we have found a very committed exclusive distributor for
the Turkish market," commented Geert Nygaard, Chief Executive Officer
of Epigenomics. "Going forward DATEKS will be an important partner in
our continuously growing distributor network for our Epi proColon
product"

Epi proColon is currently marketed by Epigenomics directly in
Germany, Austria and Switzerland. Outside this home market, it is
Epigenomics' strategy to make the CE-marked test broadly available
through a mix of direct commercialization and a distributor network.

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development for
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially
increasing the patient's chances of survival.

For development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc.
for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more
information, please visit Epigenomics' website at www.epigenomics.com

About DATEKS

DATEKS LTD. (www.dateks.com) is a pioneer in the distribution of
products for cell culture, molecular biology, and genetics in Turkey.
DATEKS successfully represents, among others, companies like Greiner
Bio-One, Biochrom, AppliChem, and Machery-Nagel some of which
distribute their products in Turkey through DATEKS for more than 20
years. While the focus initially was on products for the research
market, DATEKS since 2009 increasingly serves the diagnostics market.
The company is headquartered in Ankara with branch offices in
Istanbul, Izmir, and Antalya.

Notes for editors

Epi proColon

Epi proColon, developed by Epigenomics, is a CE-marked test kit for
the detection of methylated DNA of the Septin9 gene in blood plasma.
This Septin9 biomarker has been shown in numerous clinical studies to
be closely associated with the presence of colorectal cancer and may
aid in the detection of this common cancer. Septin9 is one of the
best and most systematically validated biomarkers for the early
detection of colorectal cancer today. In particular, the recent
PRESEPT Study was a successful prospective evaluation of Epi proColon
detection of methylated Septin9 in a cohort of about 8,000
individuals representative of a typical screening population.

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the USA have not
been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade